ArticleFrontiers in oncology2020
Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 66 citations in OpenAlex.
- Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.Breast cancer research and treatment · 2026Trial
- Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancer.Molecular cancer · 2026Article
- Gut Microbiota Metabolic Reprogramming Drives Endocrine and Immune Resistance in Hormone-Dependent Cancers.Cancers · 2026Review
- Pioneering preoperative anti-PD-1 immunotherapy enables curative resection in dMMR advanced/recurrent endometrial carcinoma: a case series (2020-2022).Discover oncology · 2026Article
- The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.Leukemia · 2026Article
- Systems pharmacology approaches decipher the anti-cancer efficacy of ethnopharmacological agents in hepatocellular carcinoma.Scientific reports · 2025Article
- Clinically friendly smart hydrogel boosts cuproptosis and PD-L1 upregulation to enhance anti-tumor immunotherapy.Materials today. Bio · 2025Article
- Differentiation and mitochondrial metabolic characteristics of CD8Cancer immunology, immunotherapy : CII · 2025Article
- Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile.Frontiers in immunology · 2025Article
- Sex bias in tumor immunity: insights from immune cells.Theranostics · 2025Review
- Effect of adipocytes on the function and activity of T cells in tumor microenvironment.Frontiers in immunology · 2025Review
- Identification and Characterization of Metastasis-Initiating Cells in ESCC in a Multi-Timepoint Pulmonary Metastasis Mouse Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer.European journal of obstetrics & gynecology and reproductive biology: X · 2024Article
- Expression of programmed death-ligand 1, IRF1 and CD8 T lymphocyte infiltration in a primary subset of breast cancer patients in Sudan.Journal of Taibah University Medical Sciences · 2024Article
- Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor.Frontiers in immunology · 2024Review
- ZC3H12A inhibits tumor growth and metastasis of breast cancer under hypoxic condition via the inactivation of IL-17 signaling pathway.Cell cycle (Georgetown, Tex.) · 2024Article
- Identification of a novel five ferroptosis-related gene signature as a promising prognostic model for breast cancer.Journal of cancer research and clinical oncology · 2023Article
- IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer.Journal of translational medicine · 2023Article
- Article
- Dual Functions of T Lymphocytes in Breast Carcinoma: From Immune Protection to Orchestrating Tumor Progression and Metastasis.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.